Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03882372
Other study ID # PPR-NHF
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date July 22, 2019
Est. completion date September 1, 2023

Study information

Verified date November 2023
Source ADIR Association
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is a major cause of disability and mortality worldwide. This systemic disease progressively leads to dyspnea and exercise capacity impairment. Pulmonary rehabilitation effectively improves exercise capacity, dyspnea and quality of life in patients with COPD. However, its benefits progressively fade over time due to several factors such as the lack of regular exercise activity, dyspnea, airway secretions, hematosis impairment and acute exacerbations which can lead to hospitalization and accelerated muscle wasting. Nasal high flow (NHF) is a support used to deliver heated and humidified high flow air (up to 60 L/min) through nasal canula providing promising physiological benefits such as positive airway pressure or upper airway carbon dioxide washout. It can be used in association with oxygen and offers the advantage to overtake the patient's inspiratory flow, providing a stable inspired fraction of oxygen. Nasal high flow has widely been studied in pediatric and adult intensive care units and seems better than conventional oxygen therapy and as effective as noninvasive ventilation with regards to mortality to treat hypoxemic acute respiratory failure. More recently, several studies have shown that long-term nasal high flow could contribute to improve exercise capacity, dyspnea, airway secretion removal, hematosis, reduced acute exacerbations and subsequent hospitalizations in patients with COPD. Based on these results, the primary aim of this study is to assess whether long-term nasal high flow treatment can help COPD patients to better maintain their endurance capacity following a course of pulmonary rehabilitation.


Description:

Experimental design: Patients achieving their last pulmonary rehabilitation session will be approached to participate in this study. Eligible patients who agree to participate in the study and sign informed consent will perform two baseline visit assessments: First visit: Incremental cardiopulmonary exercise testing. Second visit: Other baseline assessment (see outcome section), including a constant workload exercise testing at 75% of the maximal workload achieved during the incremental exercise testing. Then, patients will then be randomized to one of the following two arms: - Nasal high flow, - Usual care. After 6 months, patients will be invited to perform the same assessment as during the second baseline visit.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date September 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Chronic obstructive pulmonary disease stage III to IV; - With or without long-term oxygen therapy; - Having completed a course of pulmonary rehabilitation within the last 4 weeks (at least 18 sessions). Exclusion Criteria: - Did not complete a course of pulmonary rehabilitation; - Using noninvasive ventilation or constant positive airway pressure treatment; - Tracheostomy; - Nasal high flow intolerance; - Pregnancy or likely to be; - Unable to consent; - Patients under guardianship.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Nasal high flow
See arm description.

Locations

Country Name City State
France ADIR Association Bois-Guillaume

Sponsors (1)

Lead Sponsor Collaborator
ADIR Association

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Endurance capacity Patients will perform a constant workload exercise testing at 75% of the maximal workload achieved during the incremental cardiopulmonary exercise testing. The endurance capacity will be assessed at baseline
Primary Endurance capacity Patients will perform a constant workload exercise testing at 75% of the maximal workload achieved during the incremental cardiopulmonary exercise testing. The endurance capacity will be assessed post-intervention (after 6months)
Secondary Quality of life: Saint George's Respiratory Questionnaire Quality of life will be assessed using the Saint George's Respiratory Questionnaire. The score range from 0 (worst quality of life) to 100 (optimal quality of life). The quality of life will be assessed at baseline
Secondary Quality of life: Saint George's Respiratory Questionnaire Quality of life will be assessed using the Saint George's Respiratory Questionnaire. The score range from 0 (worst quality of life) to 100 (optimal quality of life). The quality of life will be assessed at post-intervention (after 6months)
Secondary Quality of life: Chronic Obstructive Pulmonary Disease Assessement Test Quality of life will be assessed using the Chronic Obstructive Pulmonary Disease Assessement Test The quality of life will be assessed at baseline and post-intervention for a total time frame of 6month
Secondary Quality of life: Chronic Obstructive Pulmonary Disease Assessement Test Quality of life will be assessed using the Chronic Obstructive Pulmonary Disease Assessement Test The quality of life will be assessed post-intervention (after 6months)
Secondary Exacerbations The number of chronic obstructive pulmonary disease self reported exacerbations experienced by the participants during the 6 months period of follow-up will be assessed. The number of exacerbations will be assessed for a total time frame of 6month
Secondary Hospitalizations The number of chronic obstructive pulmonary disease related hospitalizations experienced by the participants during the 6 months period of follow-up will be assessed. The number of hospitalizations will be assessed for a total time frame of 6month
Secondary Muscle function (1) : quadriceps muscle (rectus femoris) cross-sectional area The quadriceps muscle thickness will be assessed using echographies. The quadriceps muscle thickness will be assessed at baseline
Secondary Muscle function (1) : quadriceps muscle (rectus femoris) cross-sectional area The quadriceps muscle thickness will be assessed using echographies. The quadriceps muscle thickness will be assessed at baseline and post-intervention for a total time frame of 6month
Secondary Muscle function (2) : bioimpedance The overall muscle function will be assessed using bioimpedance (free fat mass minus total body water) The overall muscle function using bioimpedance will be assessed post-intervention (after 6months)
Secondary Exercise capacity Exercise capacity will be assessed using the six minutes walk test distance. The distance performed during the six-minute walk test will be assessed at baseline
Secondary Exercise capacity Exercise capacity will be assessed using the six minutes walk test distance. The distance performed during the six-minute walk test will be assessed post-intervention (after 6months)
Secondary Respiratory muscle function (1) : maximal inspiratory pressure Maximal inspiratory pressure will be assessed at baseline
Secondary Respiratory muscle function (1) : maximal inspiratory pressure Maximal inspiratory pressure will be assessed post-intervention (after 6months)
Secondary Respiratory muscle function (2) : maximal expiratory pressure Maximal expiratory pressure will be assessed at baseline
Secondary Respiratory muscle function (2) : maximal expiratory pressure Maximal expiratory pressure will be assessed post-intervention (after 6months)
Secondary Respiratory muscle function (3) : sniff test Sniff test will be assessed at baseline
Secondary Respiratory muscle function (3) : sniff test Sniff test will be assessed post-intervention (after 6months)
Secondary Parasternal electromyogram Parasternal electromyogram will be used to assess central output during maximal inspiratory and expiratory pressure measurement as during the sniff test. Moreover, parasternal electromyogram will be assessed both at rest and during nasal high flow (30L/min, 34°C). Parasternal electromyogram will be assessed at baseline
Secondary Parasternal electromyogram Parasternal electromyogram will be used to assess central output during maximal inspiratory and expiratory pressure measurement as during the sniff test. Moreover, parasternal electromyogram will be assessed both at rest and during nasal high flow (30L/min, 34°C). Parasternal electromyogram will be assessed post-intervention (after 6months)
Secondary Physical activity (1) : steps per day The number of steps per day will be recorded over a course of 14 week days using an activity monitor. Steps per day will be assessed during 14 days following inclusion
Secondary Physical activity (1) : steps per day The number of steps per day will be recorded over a course of 14 week days using an activity monitor. Steps per day will be assessed during 14 days after 6months of intervention
Secondary Physical activity (2) : time spent during activities superior to 3 metabolic equivalent per day The time spent during activities superior to 3 metabolic equivalent per day will be over a course of 14 week days The time spent during activities superior to 3 metabolic equivalent per day will be assessed 14 days following inclusion
Secondary Physical activity (2) : time spent during activities superior to 3 metabolic equivalent per day The time spent during activities superior to 3 metabolic equivalent per day will be over a course of 14 week days The time spent during activities superior to 3 metabolic equivalent per day will be assessed during 14 days after 6months of intervention
Secondary Quality of sleep (1) : Visual Analogue Scale The quality of sleep will be assessed using a aVisual Analogue Scale (ranging from 0 to 10 with 10 indicating higher sleep quality). The quality of sleep using a Visual Analogue Scale will be assessed at baseline
Secondary Quality of sleep (1) : Visual Analogue Scale The quality of sleep will be assessed using a aVisual Analogue Scale (ranging from 0 to 10 with 10 indicating higher sleep quality). The quality of sleep using a Visual Analogue Scale will be assessed post-intervention (after 6months)
Secondary Quality of sleep (2) : pittsburgh scale The quality of sleep will be assessed using the pittsburgh scale which has been validated to assess sleep quality. The scale range from 0 (major sleep difficulties) to 21 (no difficulty). The quality of sleep using the pittsburgh scale will be assessed at baseline
Secondary Quality of sleep (2) : pittsburgh scale The quality of sleep will be assessed using the pittsburgh scale which has been validated to assess sleep quality. The scale range from 0 (major sleep difficulties) to 21 (no difficulty). The quality of sleep using the pittsburgh scale will be assessed post-intervention (after 6months)
Secondary Adherence to treatment : days of utilization during the follow-up The data will be retrieved from the nasal high flow device The number of days that the nasal high flow device was used throughout the follow-up will be assessed post-intervention in the nasal high flow arm for a total time frame of 6 months
Secondary Adherence to treatment : hours of utilization per day The data will be retrieved from the nasal high flow device The number of hours of utilization per day throughout the follow-up will be assessed post-intervention in the nasal high flow arm for a total time frame of 6 months
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy